|
PRDM10 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.48179995735399E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.0216999999656E-06 |
| Normal-vs-Stage2 |
4.12469999999665E-06 |
| Normal-vs-Stage3 |
3.1662999999682E-08 |
| Normal-vs-Stage4 |
6.56120000552818E-08 |
| Stage1-vs-Stage2 |
2.214000E-01 |
| Stage1-vs-Stage3 |
5.870300E-02 |
| Stage1-vs-Stage4 |
2.030100E-02 |
| Stage2-vs-Stage3 |
8.672600E-01 |
| Stage2-vs-Stage4 |
5.294000E-01 |
| Stage3-vs-Stage4 |
6.039400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.81890000231044E-09 |
| Normal-vs-AfricanAmerican |
9.940700E-03 |
| Normal-vs-Asian |
1.076360E-03 |
| Caucasian-vs-AfricanAmerican |
2.775400E-01 |
| Caucasian-vs-Asian |
1.916780E-01 |
| AfricanAmerican-vs-Asian |
9.255600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.45479997335241E-09 |
| Normal-vs-Female |
1.26720000048763E-07 |
| Male-vs-Female |
2.343000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.39289999998316E-06 |
| Normal-vs-Age(41-60Yrs) |
2.39699999959875E-07 |
| Normal-vs-Age(61-80Yrs) |
1.42339999786856E-08 |
| Normal-vs-Age(81-100Yrs) |
1.081640E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.480000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.015900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.280010E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.616000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.865000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.047800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.426800E-04 |
| Classical-VS-Follicular |
2.023400E-01 |
| Classical-VS-Other |
3.453400E-01 |
| Classical-VS-Normal |
7.49070000027885E-07 |
| Tall-VS-Follicular |
7.842500E-02 |
| Tall-VS-Other |
6.056400E-01 |
| Tall-VS-Normal |
9.57549994851092E-09 |
| Follicular-VS-Other |
7.050400E-01 |
| Follicular-VS-Normal |
1.57449000000032E-05 |
| Other-VS-Normal |
1.222350E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.46209999849634E-08 |
| Normal-vs-N1 |
2.85929999999102E-06 |
| N0-vs-N1 |
7.887400E-01 |
|
|
